ArticleInorganica chimica acta2012
Metallocenes as Target Specific Drugs for Cancer Treatment.
Article in Inorganica chimica acta, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Enantiomerically PureMolecules (Basel, Switzerland) · 2025Review
- A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95.Life science alliance · 2023Article
- Steroids Bearing Heteroatom as Potential Drugs for Medicine.Biomedicines · 2023Review
- Anticancer Tungstenocenes with a Diverse Set of (Pharmaceutics · 2023Article
- Mass Spectrometric Evaluation of β-Cyclodextrins as Potential Hosts for Titanocene Dichloride.International journal of molecular sciences · 2021Article
- Synthesis, Characterization, and Antiproliferative Activity of Novel Chiral [QuinoxP*AuClMolecules (Basel, Switzerland) · 2020Article
- Interaction of metallocene dichlorides with apo-human transferrin: A spectroscopic study and cytotoxic activity against human cancer cell lines.International journal of molecular biology (Edmond, Okla.) · 2020Article
- Impact of Molybdenum Compounds as Anticancer Agents.Bioinorganic chemistry and applications · 2019Review
- TrappingMolecules (Basel, Switzerland) · 2018Article
- Para-Substituted Functionalised Ferrocene Esters with Novel Antibacterial Properties.Journal of clinical and diagnostic research : JCDR · 2018Article
- Crystal structure of bis-[4-(1H-pyrrol-1-yl)phen-yl] ferrocene-1,1'-di-carboxyl-ate: a potential chemotherapeutic drug.Acta crystallographica. Section E, Crystallographic communications · 2015Article
- Ferrocenes as potential chemotherapeutic drugs: synthesis, cytotoxic activity, reactive oxygen species production and micronucleus assay.Bioorganic & medicinal chemistry · 2015Article
- Functionalized ferrocenes: The role of the para substituent on the phenoxy pendant group.Journal of organometallic chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The application use of organometallic compounds into the cancer research was established in the late 1970s by Köpf-Maeir and Köpf. This new research area has been developed for the past thirty years. In the early 1980s, Jaouen and coworkers recognized the potential application of organometallic compounds vectorized with pendant groups that can deliver the drug to certain specific receptors. This is what is called nowdays Target Specific Drugs. This review will focus on metallocenes vectorized with steroids derivatives of hormones, nonsteroidal and selective endrocrine modulator.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.